A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Inclusion Criteria: Patients will be enrolled in this study only if they meet all of the following criteria: * Informed Consent Form signed by the patient or patient's legal representative. * Male or female, aged 16-70 years, inclusive. * For Group 1, patients with acute thoracic (T2-T12) spinal cord injury; for Group 2, patients with acute cervical (C4-T1) spinal cord injury. The site of surgery should be able to accommodate a minimum volume of 2 mL of fibrin sealant. * Scheduled to undergo spinal decompression surgery or other interventional spinal surgery (e.g., fixation) within 7 days of injury. * ASIA Impairment Scale grade of A (complete, no motor or sensory function present in the sacral segment) as assessed within 12 hours before surgery. * Able to communicate effectively to obtain informed consent and to ensure neurological examination. Exclusion Criteria: Patients will not be enrolled in this study if they meet one of the following criteria: * Use of any experimental drug, or participation in any clinical trial, within 30 days prior to surgery. * History of adverse reaction to fibrin sealant. * History of hypersensitivity to bovine products. * Any medical condition that may interfere with the ASIA assessments. * Clinically significant neurological, cardiac, respiratory, hepatic, or renal disease or malignancy. * Hemophilia or other bleeding abnormality as defined by: * Platelet level lower than 100 X 109/L * Activated partial thromboplastin time or interna…